Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1373940 | Bioorganic & Medicinal Chemistry Letters | 2009 | 5 Pages |
Abstract
A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jingrong Cao, Huai Gao, Guy Bemis, Francesco Salituro, Mark Ledeboer, Edmund Harrington, Susanne Wilke, Paul Taslimi, S. Pazhanisamy, Xiaoling Xie, Marc Jacobs, Jeremy Green,